Viridian Therapeutics, Inc.
VRDN
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.6B
$22.92
▼ -0.17%
P/E
-6.49
Mkt Cap
$2.6B
52-Wk Range
$13.18–$34.29
52-Week Range
$13.18 - $34.29
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 15.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Focused pipeline targeting IGF-1R pathway with validated mechanism of action in TED
- Humanized monoclonal antibody platform enabling potentially improved safety and efficacy profiles
- First-mover advantage in IGF-1R antibody development for thyroid eye disease indication
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Clinical trial progression of VRDN-001 with potential for breakthrough therapy designation in TED
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+45.7% over 3m
Quality
Excellent
High-growth business (500% revenue growth, 100% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying VRDN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 6, 2026
Reported EPS of -$1.05 vs -$1.03 consensus (-1.9% surprise). Revenue of $284.0K vs $56.4K expected (+403.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.9%
Revenue trend · last 8Q
—
0%
0%
+4%
+81958%
+83%
+96%
+279%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$86.0K
$72.0K
$72.0K
$75.0K
$70.6M
$132.0K
$141.0K
$284.0K
Margins · last 8Q
Gross
100.0%
Operating
—
Profit
-44760.2%
Wall Street consensus
9 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$35.00
▲ +52.7% vs $22.92
Latest: RBC Capital · Aug 7, 2026
3 analysts covering
vs Industry
How VRDN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related